A Phase 4 interventional study of rituximab [MabThera/Rituxan] and methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 5 sites in Morocco. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-10.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 104th largest by enrollment, is one of 9 that started in 2007, is one of 38 in phase 4, and was the 39th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 9 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 129th largest by enrollment of the 141 interventional ones that give a count, is one of 15 that started in 2007, is one of 28 in phase 4, and was the 63rd registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and efficacy of MabThera in patients with active rheumatoid arthritis who have had an inadequate response or were intolerant to treatment with methotrexate. Eligible patients will receive MabThera (1000mg by intravenous infusion) on days 1 and 15, and background methotrexate (oral or subcutaneous dose of 10-25mg weekly). After the initial study period of 24 weeks, eligible patients may receive up to 3 re-treatments with MabThera. The anticipated time on study treatment is 1-2 years, and the target sample size is \<100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rituximab [MabThera/Rituxan] · Drug: methotrexate
Drug page: Rituximab
1000mg iv on days 1 and 15
10-25mg weekly
Percentage of Participants With an Adverse Event (AE)
Time frame: Week 104
Disease Activity Score Based on 28-Joint Count (DAS28)
DAS28 was calculated from the number of swollen joints and tender joints using the 28 joint count; the erythrocyte sedimentation rate (ESR) measured in millimeters per hour \[mm/hr\]); and the Patient's Global Assessment of disease activity (participant-rated visual analog assessment \[VAS\]) with transformed scores with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. Overall, a DAS28 score of less than or equal to (≤) 3.2 equals (=) low disease activity, and a DAS28 score of greater than (\>) 3.2 to 5.1 = moderate to high disease activity.
Time frame: Day 1 and Week 24
Percentage of Participants With a DAS28 Response by European League Against Rheumatism (EULAR) Category
DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline greater than (\>)1.2 with DAS28 less than or equal to (≤)3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or change from baseline \>0.6 to ≤1.2 with DAS28 ≤5.1; non-responders: change from baseline ≤0.6 or change from baseline \>0.6 and ≤1.2 with DAS28 \>5.1.
Time frame: Screening, Day 1, and Weeks 24 and 104
Percentage of Participants With Changes in Bone Density
Change in bone density in participants untreated with bisphosphonates was classified as percentage of participants with osteoporosis, osteopenia, or normal. In some participants, no determinations were available.
Time frame: Screening, Weeks 48 and 104
| Milestone | Rituximab 1000 Milligrams (mg) |
|---|---|
| Started | 15 |
| Completed | 6 |
| Not completed | 9 |
| Withdrew: Failure to return | 8 |
| Withdrew: Withdrawal by subject | 1 |
| percentage of participants | Rituximab 1000 mg |
|---|---|
| Percentage of Participants With an Adverse Event (AE) | 26.7 |
DAS28 was calculated from the number of swollen joints and tender joints using the 28 joint count; the erythrocyte sedimentation rate (ESR) measured in millimeters per hour \[mm/hr\]); and the Patient's Global Assessment of disease activity (participant-rated visual analog assessment \[VAS\]) with transformed scores with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. Overall, a DAS28 score of less than or equal to (≤) 3.2 equals (=) low disease activity, and a DAS28 score of greater than (\>) 3.2 to 5.1 = moderate to high disease activity.
| scores on a scale | Rituximab 1000 mg |
|---|---|
| Day 1 | 5.79 ± 1.03 |
| Week 24 | 4.41 ± 1.88 |
DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline greater than (\>)1.2 with DAS28 less than or equal to (≤)3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or change from baseline \>0.6 to ≤1.2 with DAS28 ≤5.1; non-responders: change from baseline ≤0.6 or change from baseline \>0.6 and ≤1.2 with DAS28 \>5.1.
| percentage of participants | Rituximab 1000 mg |
|---|---|
| ≤3.2 at Screening | 0 |
| >3.2 and ≤5.1 at Screening | 22.2 |
| >5.1 at Screening | 77.8 |
| ≤3.2 at Day 1 | 0 |
| >3.2 and ≤5.1 at Day 1 | 33.3 |
| >5.1 at Day 1 | 66.7 |
| ≤3.2 at Week 24 | 37.5 |
| >3.2 and ≤5.1 at Week 24 | 37.5 |
| >5.1 at Week 24 | 25.0 |
| ≤3.2 at Week 104 | 33.3 |
| >3.2 and ≤5.1 at Week 104 | 33.3 |
| >5.1 at Week 104 | 33.3 |
Change in bone density in participants untreated with bisphosphonates was classified as percentage of participants with osteoporosis, osteopenia, or normal. In some participants, no determinations were available.
| percentage of participants | Rituximab 1000 mg |
|---|---|
| Osteoporosis, Screening | 20 |
| Osteopenia, Screening | 46.7 |
| Normal, Screening | 0 |
| Not determined, Screening | 33.3 |
| Osteoporosis, Week 48 | 6.7 |
| Osteopenia, Week 48 | 13.3 |
| Normal, Week 48 | 6.7 |
| Not determined, Week 48 | 73.3 |
| Osteoporosis, Week 104 | 0 |
| Osteopenia, Week 104 | 40 |
| Normal, Week 104 | 0 |
| Not determined, Week 104 | 60 |
Collected over Adverse events were collected from signing of informed consent through the end of the follow-up period (Week 104).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab 1000 mg | — | 0/15 (0%) | 4/15 (26.7%) |
| Event | Rituximab 1000 mg |
|---|---|
| FeverGeneral disorders | 1/15 |
| Scalp infectionInfections and infestations | 1/15 |
| RashSkin and subcutaneous tissue disorders | 1/15 |
| Rash of faceSkin and subcutaneous tissue disorders | 1/15 |
| Diffuse skin rashSkin and subcutaneous tissue disorders | 1/15 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/15 |
| Tightening of throat and tongueRespiratory, thoracic and mediastinal disorders | 1/15 |
| Difficulty breathingRespiratory, thoracic and mediastinal disorders | 1/15 |
Intent-to-Treat (ITT) population: all participants who received any part of an infusion.
| Age, Continuous(years) | Rituximab 1000 mg |
|---|---|
| Mean | 37 ± 12 |
| Sex: Female, Male(Participants) | Rituximab 1000 mg |
|---|---|
| Female | 10 |
| Male | 5 |
The record gives a start of Oct 2007, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 3 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methotrexate